Enovis Co. (NYSE:ENOV) Shares Bought by Fmr LLC

Fmr LLC grew its position in Enovis Co. (NYSE:ENOV) by 20.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,840 shares of the company’s stock after acquiring an additional 484 shares during the quarter. Fmr LLC’s holdings in Enovis were worth $122,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ENOV. Benjamin F. Edwards & Company Inc. lifted its position in Enovis by 28.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after acquiring an additional 371 shares during the period. Aigen Investment Management LP grew its position in Enovis by 5.1% in the 3rd quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock valued at $381,000 after buying an additional 430 shares during the last quarter. Ridgewood Investments LLC acquired a new position in Enovis in the 2nd quarter valued at $44,000. State of Alaska Department of Revenue raised its position in Enovis by 20.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,482 shares of the company’s stock worth $279,000 after buying an additional 1,115 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of Enovis in the 3rd quarter worth $55,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ENOV. JMP Securities initiated coverage on shares of Enovis in a report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $65.00 target price on shares of Enovis in a research note on Thursday, November 7th. Finally, Evercore ISI decreased their price target on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $67.00.

Enovis Stock Up 1.5 %

Enovis stock opened at $43.12 on Monday. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -19.69 and a beta of 1.94. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The stock’s fifty day moving average is $44.74 and its two-hundred day moving average is $44.41.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.11. The firm had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same period last year, the firm posted $0.56 EPS. Analysts predict that Enovis Co. will post 2.79 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.